BofA lowered the firm’s price target on United Therapeutics (UTHR) to $314 from $328 and keeps an Underperform rating on the shares. The firm ...

United Therapeutics has a 12-month low of $221.53 and a 12-month high of $417.82. The business’s fifty day moving average price is $349.12 and its 200 day moving average price is $358.27.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Molecular Partners (MOLN – Research Report), ...

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 04, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that ...

BOSTON, March 15, 2025 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical ... disease affecting over 40,000 patients in the United States and many more worldwide. There are no approved ...

Skyhawk presents today on its novel SKY-0515 small molecule RNA splicing modulator targeting Huntington's Disease to members of the Huntington's Disease Youth Organization, at the annual HYDO ...

UN says renewed Gaza violence makes hostage return more distant The United Nations said on Thursday that each day of renewed violence in Gaza makes the return of the remaining hostages held there ...

Ellie Wood, the producer behind Netflix film The Dig, has struck a development deal with Banijay UK and is working an adaptation of Barbara Pym’s ‘Excellent Women’ novels. Under terms of the ...

The Buccaneers are back in a set of first-look photos and a teaser clip for Season 2 of the Apple TV+ show, which will return to society and streaming June 18, 2025. The eight-episode second ...